Regenerative Medical Technology Group (RMTG) and Global Stem Cells Group (GSCG)

RMTG/GSCG operates a vertically integrated regenerative medicine platform that combines physician education, biologics manufacturing, premium clinical delivery and a digital data layer to create recurring revenue across products, services and subscriptions.

Core business model

• Vertically integrated platform combining education, manufacturing, clinical delivery and digital enablement.
• Four-pillar strategy for 2026:
  • ISSCA education to acquire physicians and standardize clinical protocols.
  • Cellgenic manufacturing and product portfolio as the high-margin product engine.
  • Premium clinical centers to generate revenue and validate protocols.
  • International expansion as the mechanism for global scaling.
• A closed-loop ecosystem that drives demand, supplies quality-controlled biologics, validates protocols through clinical application, and supports scalable recurring revenue via digital tools.

Four pillars

ISSCA (International Society for Stem Cell Applications)

• Global leader in regenerative medicine education.
• Engages physicians through events, certifications and curricula.
• Expands online certifications and post-graduate training (diplomas, fellowships) to establish standards-based practice.

Cellgenic (manufacturing and product innovation)

• Operational manufacturing infrastructure for exosomes, mesenchymal stem cells (MSCs), peptides and other biologics.
• Product portfolio includes next-generation exosome formulations, peptides and combination therapies (MSC + exosomes + peptides).
• Supplies products, ready-to-use clinical kits and processing systems to physicians and clinics participating in ISSCA programs.
• Focus on high-margin, recurring revenue from consumables and integrated supply with controlled environments and standardized protocols.

Premium clinical network (Cellular Institute and Stem Cell Center)

• Five-star regenerative medicine centers emphasizing patient experience and expanded service lines (biohacking, anti-aging, hormone therapy, aesthetic medicine and advanced cellular therapies).
• Integrates AI-assisted diagnostics and standardized protocols.
• Functions as both direct revenue channels (high-ticket procedures) and validation platforms for real-world data, protocol refinement and product improvement.
• Prepared for franchise and joint-venture models to scale globally.

International market expansion

• “Land and expand” strategy targeting high-growth regions: Latin America, Middle East, Southeast Asia, South Asia and Europe.
• Rollout sequence: ISSCA education, Cellgenic product distribution, then clinical partnerships to generate network effects and revenue.
• Argentina positioned as a regulatory stronghold and model for replication across Latin America.

Digital and data backbone

• Development of the ISSCA AI Platform and ISSCA App to support:
  • Clinical decision support, protocol recommendations, patient management and workflow optimization.
  • Global physician networking, education access and community engagement.
• Intends to generate recurring digital subscriptions, data-driven insights and stronger physician retention.

Products and services

• Cellgenic product portfolio: exosomes, MSCs, peptides, combination therapies and related biologics.
• Ready-to-use clinical kits and processing systems.
• ISSCA training, certifications, events and online programs.
• Premium clinical treatments delivered through the Cellular Institute and affiliated clinics.
• Equipment sales, licensing, partnerships and digital subscriptions as part of a diversified revenue model.

Geographic and regulatory actions

• Argentina: aligned with local regulatory framework for advanced biologics and cell therapy manufacturing; exclusive distribution, standardized protocols and a national ecosystem for education, products and clinical services.
• Global entries include Latin America (Argentina, Brazil, Mexico), Middle East (UAE, Saudi Arabia), Southeast Asia (Indonesia), South Asia (Pakistan) and Europe (Portugal, Spain, Italy).
• Dubai facility: launch delayed; 2026 plans reflect continued international expansion.

Key facilities and operations

• Cancún, Quintana Roo, Mexico: central hub for patient care, physician training and advanced manufacturing (MSC, exosomes, peptides, biologics).
  • On-site biologics processing lab, clean room, distribution logistics and AI-supported decision tools.
  • COFEPRIS-accredited for compliant stem cell collection, banking and manufacturing.
• Multiple leased properties in Cancún and nearby areas to support clinical and manufacturing growth.
• Long-term lease extension through 2029 supports operational stability.

Capital structure, liquidity and governance highlights

• Independent auditor issued a going-concern opinion, indicating material doubt about continued operations without additional financing or revenue growth.
• Unsecured promissory notes totaling approximately $1.16 million matured and are in default (as of 2025).
• Potential acceleration of up to $16.6 million in secured debt if defaults are not resolved.
• Series AA Preferred Stock concentrates voting power (aggregate 67% of voting rights for certain holders); current holders include the CEO and Benito Novas.
• Authorized capital: 100,000,000 common shares and 11,000,000 preferred shares.
• Publicly traded on OTC Markets as a smaller reporting company.
• As of 12/31/2025, substantial issuances of common stock, options, warrants and convertible securities create potential dilution risk.

2025–2026 milestones and commercial activities

• ISSCA delivered 15 international events across five continents in 2025 and expanded online certifications and specialty programs.
• ISSCA Global Summit (Cancún, 2025) drew more than 470 medical professionals and served as a major marketing and enrollment driver.
• Progress toward clinical network expansion and franchising readiness to scale global centers and training hubs.
• 2026 strategic focus: ecosystem optimization, accelerated clinical network franchising, deeper AI-driven personalization and data monetization, continued product innovation and selective entry into regulated markets such as North America.

Risk areas

• Regulatory and legal risks across international markets; potential need for future regulatory clearances in certain jurisdictions.
• Dependence on key management and leadership; absence of directors and officers (D&O) insurance noted.
• Intellectual property risks and potential for reverse engineering of exosome and peptide protocols.
• Cybersecurity and data privacy risks related to online training and global data handling.
• Potential dilution and control concentration due to preferred stock and convertible instruments.

Summary

RMTG/GSCG markets regenerative medicine as an integrated platform that combines ISSCA education, Cellgenic manufacturing, premium clinical centers and international expansion, supported by a developing AI and app-based digital layer. The company focuses on recurring revenue from product consumables, education, clinical services and digital subscriptions while pursuing global scale and product innovation, amid financial and regulatory risks that affect near-term liquidity and governance.